Zevaskyn
Payments companies reported to CMS as associated with Zevaskyn. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zevaskyn, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zevaskyn
These are the largest totals companies reported as associated with Zevaskyn. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Eric Crombez | Los Angeles, CA | Clinical Genetics (M.D.) | $14,375.00 |
| Joyce Teng | Palo Alto, CA | Pediatric Dermatology | $7,151.06 |
| Amy Paller | Chicago, IL | Pediatrics | $6,474.98 |
| Nessa Aghazadeh Mohandesi | Rochester, MN | Dermatology | $4,276.17 |
| Maria Buethe | Orange, CA | Pediatric Dermatology | $3,921.03 |
| Emily Gorell | Aurora, CO | Dermatology | $3,229.17 |
| Lawrence Schachner | Miami, FL | Dermatology | $3,097.60 |
| Anna Bruckner | Aurora, CO | Pediatric Dermatology | $3,049.98 |
| Lara Wine Lee | Charleston, SC | Pediatric Dermatology | $3,025.00 |
| Mercedes Gonzalez | Miami, FL | Dermatology | $3,025.00 |
Prescribed Zevaskyn?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.